jueves, 12 de noviembre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 29, 2026

P&G Announces Fourth Quarter and Fiscal Year 2026 Results

View original at finance.yahoo.com
P&G Announces Fourth Quarter and Fiscal Year 2026 Results Q4 '26: Net Sales +2%; Organic Sales 0%; Diluted EPS -15%; Core EPS -3% FY '26: Net Sales +3%; Organic Sales +1%; Diluted EPS +2%; Core EPS +1% CINCINNATI, July 29, 2026--(BUSINESS WIRE)--The Procter & Gamble Company (NYSE:PG) reported fourth quarter and fiscal…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Fiscal 2026 was a year of foundation building while continuing to grow sales and profit and return high levels of cash to shareowners despite a very challenging geopolitical and economic environment; expects progress in fiscal 2027 by doubling down on strategy, prioritizing the consumer, and funding investments with a strong productivity program.

    60% confidence

Data points we hold from this source

Procter & Gamble · core eps6.89 USD
Procter & Gamble · adjusted free cash flow productivity100 percent
Procter & Gamble · organic sales growth0 percent
Procter & Gamble · operating cash flow19.6 USD
Procter & Gamble · net income16.1 USD
Procter & Gamble · eps6.62 USD
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,995
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,995 hechos verificados con la fuente5,565 documentos fuente archivados
Consulta estos datos → isubstrate.com
P&G Announces Fourth Quarter and Fiscal Year 2026 Results — Source | Via News | es.VIA.NEWS